Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Already USFDA-approved, under-the-skin jab can be administered in just seven minutes to the patient. This is dramatic cut ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk ...

To our knowledge, the SOGUG-AUREA trial showed, for the first time, that the combination of atezolizumab with split doses of cisplatin and gemcitabine was effective and safe for patients with mUC ,” ...

Treatment with atezolizumab resulted in a median overall survival duration of 15.9 months, with an objective response rate of 23%, rising to 28% in patients with the highest levels of PD-L1 ...

Background: Radical cystectomy is the standard of care for patients with BCG-unresponsive high risk non-muscle invasive bladder cancer (NMIBC). Based on the reported efficacy of atezolizumab in ...

Atezolizumab after surgery and chemotherapy reduced risk for disease recurrence or death among patients with stage II to stage IIIA non-small cell lung cancer, according to research presented ...

Atezolizumab first received FDA approval in 2016 for the treatment of metastatic non-small cell lung cancer (NSCLC) with progression of disease following traditional chemotherapy regimens.

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented ...

Background: Atezo + bev has been approved globally for pts with unresectable HCC who have not received prior systemic therapy, based on results from IMbrave150 (NCT03434379). At a median of 8.6 mo ...

Atezolizumab is an inhibitor of cell programmed death ligand 1 (PDL1) and is in several phase 3 trials in a number of tumor types. It has received breakthrough designation from the US Food and ...